|Videos|April 5, 2021

2-year follow-up shows Jatenzo is effective, safe in men with hypogonadism

Ronald S. Swerdloff, MD, MACP, discusses 2-year follow-up data from an open-label, multicenter study of Jatenzo (testosterone undecanoate) oral capsules in men with hypogonadism. The findings showed that Jatenzo kept testosterone levels in the normal range with a similar safety profile as other testosterone replacement therapies (TRTs). Of note, Swerdloff says that over the 2 years, Jatenzo showed “no evidence of liver toxicity,” whereas some TRTs have been associated with liver toxicities.

Swerdloff is a senior investigator at the Lundquist Institute, chief, Division of Endocrinology, Harbor-UCLA Medical Center, and professor of Medicine, David Geffen School of Medicine at UCLA.


Related to this article

Rethinking Testosterone Therapy After the FDA Label Revisions
Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.